All Categories
Technologies Involved in mRNA Synthesis

Technologies Involved in mRNA Synthesis

Home >  Modality  >  Nucleic Acids  >  Messenger RNA (mRNA)  >  Technologies Involved in mRNA Synthesis

Modality

Technologies Involved in mRNA Synthesis

In Vitro Synthesis of mRNA

The major components of mRNA are 5’-cap, 5’-UTR, open reading frame (ORF), 5’-UTR, and 5’ poly A tail, which are essential for maintaining mRNA function. Researchers have used a variety of methods to identify and optimize mRNA sequences and structures.

The synthesis of mRNA is performed on the basis of in vitro transcript (IVT) using linear DNA templates, RNA polymerases (T3, T7, or SP6), unmodified or modified nucleotides, enzymes, and appropriate reagents.

5’ Cap Modification

The sequences of mature mRNA from eukaryocyte show a 7-methylguanosine (m7G) cap at the 5’ end, which improves mRNA stability and translational efficiency. There are two general methods for capturing mRNA in vitro. First, mRNA can be capped along with in vitro transcript by adding a cap analog of the m7GpppG structure (e.g., CleanCap) to the IVT system. This co-transcriptional capping method provides a natural 5' capsule structure and increases the capping efficiency to nearly 90-99%. Secondly, mRNA mapping can also be accomplished by mapping enzyme reactions following the in vitro transcription reaction.

PolyA Modification

Poly(A) tail also extends the half-life of mRNA in vivo and improves mRNA translation efficiency. The length of the amplified poly(A) tail should be 100-300 nucleotides. Additionally, modified adenosine increases the stability of the poly A tail against cellular RNase degradation. Poly A tail can be inserted by in vitro transcription using DNA template encoding poly A, thereby resulting in a specific poly A sequence length. Recombinant poly A polymerase can also be used by enzymatic polyadenylation after mRNA transcription.

Nucleotides Modification

Modified nucleosides can inhibit pattern recognition receptors (PRR) recognition and /or activation and enhance the efficacy of mRNA vaccines in two totally different ways. he addition of certain chemically modified nucleosides including pseudouridine (ψ), 1-methylpseudouridine (m1ψ), thiouridine (s4U) and 5-methylcytosine (m5C) can prevent the activation of TLR7/8 and other innate immune receptors, which significantly reduce the immunogenicity of mRNA.

mRNA Delivery System

To maintain the function of mRNA, it needs to enter the host cytoplasm and express specific antigens. One of the most difficult challenges facing mRNA vaccines and therapeutics lies in delivering mRNA into target cells with sufficiently high translation levels for it requires highly specific and efficient mRNA delivery systems. Several mRNA delivery vectors have been developed and used, including dendritic cells (DCs), protamine, cationic polymers, and cationic liposomes.

Complexes of cationic lipids with mRNA and other preparations can collectively form 80-200 nm-sized nanoparticles named lipid nanoparticles (LNPs). As one of the most advanced mRNA delivery systems, LNP includes ionizable cationic lipids, natural phospholipids, cholesterol and polyethylene glycol (PEG). Several RNA vaccines and therapies (siRNA and mRNA) approved by the U.S. Food and Drug Administration are based on LNP delivery systems.

Yaohai Bio-Pharma Offers One-Stop Solution for RNA

Catalog RNA Products

  • Catalog mRNA Products
  • Catalog saRNA Products
  • Catalog circRNA Products

Custom RNA Synthesis

  • Custom mRNA Synthesis
  • Custom saRNA Synthesis
  • Custom circRNA Synthesis

mRNA CDMO Services

  • Process Development
  • GMP Manufacturing
  • Aseptic Fill and Finish
  • Analysis and Testing
Custom Deliverables

Grade

Deliverables

Specification

Applications

non-GMP

Drug Substance, mRNA

0.1~10 mg (mRNA)

Preclinical research such as cell transfection, Analytical method development, Pre-stability studies, Formulation development

Drug Product, LNP-mRNA

GMP, Sterility

Drug Substance, mRNA

10 mg~70 g

Investigational new drug (IND), Clinical trial authorisation (CTA), Clinical trial supply, Biologic license application (BLA), Commercial supply

Drug Product, LNP-mRNA

5000 vials or pre-filled syringes/ cartridges

Get a Free Quote

Get in touch